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Purpose: Patients with poorly controlled allergic rhinitis (AR) experience nasal symptoms, 
sleep disturbances, activity impairment, and decreased quality-of-life (QoL). MP-AzeFlu is 
safe and effective for moderate-to-severe seasonal and perennial AR, but its impact on QoL 
requires investigation in the real-world, especially among phenotypes of immunoglobulin 
(Ig)E-mediated AR. This subanalysis of an observational study evaluated response to MP- 
AzeFlu via assessment of sleep quality and trouble with daily activities.
Patients and Methods: This multicenter, prospective, non-interventional, real-life study 
included a convenience sample of patients with a history of moderate-to-severe AR presenting 
with acute AR symptoms (visual analog scale [VAS] ≥50 mm). Over approximately 14 days of 
treatment with MP-AzeFlu (137 µg azelastine HCL and 50 µg fluticasone propionate adminis-
tered via single 0.137-mL spray in each nostril twice daily), changes in sleep quality and trouble 
with daily work, school, social, and outdoor activities were evaluated using a VAS for the entire 
study population and for four subgroups based on IgE response phenotype. VAS scores ranged 
from “not at all troubled” (0 mm) to “extremely troubled” (100 mm).
Results: Following MP-AzeFlu treatment, mean VAS scores for sleep quality impairment and 
work or school impairment decreased from 55.2 mm at baseline to 22.1 mm and 57.6 mm at 
baseline to 23.0 mm, respectively, after ~14 days. Similar results were observed for mean VAS 
scores for impairment of social activity (55.1 mm to 22.4 mm) and impairment of outdoor 
activity (64.4 mm to 25.0 mm). For all VAS scores, results were similar across populations, 
regardless of phenotype of IgE-mediated disease, comorbidity, age, and sex.
Conclusion: MP-AzeFlu relieves symptoms and improves patient-reported QoL, illustrated 
by better sleep quality and less impairment of work, school, social, and outdoor activities 
after 14 days. The QoL benefits of MP-AzeFlu were consistent regardless of the phenotype 
of IgE-mediated disease.
Registration: Clinical Trial Registration (CTR) Number: EUPAS23075. Trial Register 
Date: March 12, 2018. First patient visit; Last patient visit: February 2018; April 2019.
Keywords: azelastine hydrochloride, daily activities, fluticasone propionate, sleep
Introduction
Allergic rhinitis (AR) comprises a variety of nasal symptoms, including congestion, 
itching, rhinorrhea, sneezing, and loss of smell.1 AR is frequently accompanied by ocular 
symptoms, such as itchy or watery eyes and redness, which are referred to as allergic 
rhinoconjunctivitis.1–3 According to Allergic Rhinitis and its Impact on Asthma (ARIA) 
severity criteria, the majority of patients experience moderate-to-severe disease.4
Severity of disease can have a profound impact on quality-of-life (QoL; eg, 
sleep disturbances, emotional problems, impairment in activities of daily life or 
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social functioning),1 and on work productivity and school 
performance.1,5 AR impairs work productivity to a greater 
degree than hypertension and type 2 diabetes.5 The coex-
istence of AR in children with asthma further increases the 
burden of sleep-related breathing disorders.6
A study of adults with allergic occupational rhinitis 
demonstrated impaired QoL and work productivity.7 In 
a study of 101 adolescents and 41 children with moderate 
and severe persistent AR, medical treatment failure was 
associated with worse QoL outcomes.8 Furthermore, there 
was a significant correlation between visual analog scale 
(VAS) scores for nasal symptoms and QoL 
questionnaires.8
Results from a systematic review demonstrate that 
approximately 2.3% of 1,666 participants from a pooled 
analysis of six studies using the Work Productivity and 
Activity Impairment Allergy Specific (WPAI-AS) ques-
tionnaire missed work time, with 35.5% of 6,536 partici-
pants from a pooled analysis of 11 studies using the 
WPAI-AS questionnaire experiencing impaired work per-
formance resulting from AR.9 Symptom severity was asso-
ciated with a greater impact of AR on work productivity. 
Pharmacologic treatment of AR had a beneficial effect on 
work productivity. A study of physical activity in 1,137 
German teens (mean age=15.6 years; 47% male) using 
1-week accelerometry revealed an independent association 
between asthma and rhinitis and low physical activity in 
boys, but not in girls.10
Using the Medical Expenditure Panel Survey, self- 
reported information on demographic and socioeconomic 
characteristics, and health conditions, insurance status, 
healthcare use, and missed workdays were collected.11 
Among 225.1 million adults, the estimated prevalence of 
AR was 7.9±0.3%. AR was associated with significantly 
increased limitations in work, social, and cognitive 
activity.11 In a case-control study of 1,834 students aged 
15–17 years sitting for examinations in mathematics, 
English, and science, those reporting AR symptoms on 
an examination day were 40% more likely to drop 
a grade between practice and final examinations compared 
with students who did not report AR symptoms.12 
Furthermore, those who reported taking sedating antihis-
tamines during examinations were 70% more likely to 
drop a grade.12 Uncontrolled AR has also been associated 
with a negative impact on sexual functioning and impaired 
driving ability.13–15
MP-AzeFlu is indicated for the relief of symptoms of 
moderate-to-severe seasonal and perennial AR and has 
proved effective for the relief of AR symptoms;16–20 how-
ever, its impact on patient QoL under real-world condi-
tions has not been reported in the literature to date. The 
Rhinitis Quality-of-Life Questionnaire (RQLQ) was used 
previously in the categorization of AR severity, but the 
impact of treatment on RQLQ scores was outside the 
scope of the study.21
AR symptoms are often assessed with a VAS, a simple, 
validated, and widely used instrument.22 A VAS was used 
for assessment of QoL in this study. The primary purpose 
of this real-life observational study was to investigate 
associations between patient-reported changes in sleep 
quality and trouble with daily work and social activities, 




This multinational, multicenter, prospective, non- 
interventional real-life observational study was conducted 
in six European countries (Austria, Germany, Czech 
Republic, Hungary, the Netherlands, and Ireland) to eval-
uate the use of MP-AzeFlu. The recruitment period lasted 
14 months, from February 21, 2018 (recruitment of first 
patient), to April 30, 2019 (date of last electronic case 
report form submission).
Patients attended an inclusion visit (Day 0) and 
a control visit after ~14 days; alternatively, the patient 
card could be sent by mail following the treatment period. 
The inclusion decision had to be made independently from 
and after the decision to prescribe MP-AzeFlu to the 
patient. Symptom severity on days 0, 1, 3, 7, and ~14, 
and quality of sleep and daily activities on days 0, 7, and 
~14 were assessed by the patient on the VAS printed on 
the patient card.
Patients
The treatment population for this study was a convenience 
sample of adolescent and adult patients who had a history of 
moderate-to-severe AR for which MP-AzeFlu had been pre-
scribed for the first time. Physicians who routinely managed 
patients with AR and used a VAS for symptom assessment of 
patients with AR as recommended by MAladies Chroniques 
pour un VIeillissement Actif en Languedoc-Roussillon 
(MACVIA)/ARIA guidelines were invited to participate.
To be included in the study, all the following criteria 
had to be met:
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● First time prescription of MP-AzeFlu.
● History of moderate-to-severe symptoms of AR.
● Age ≥12 years.
● Acute symptoms of AR on the day of inclusion (VAS 
score ≥50 mm).
● Written informed consent by patient and (if applic-
able) caregiver for patients aged ≤18 years.
● Ability to understand the instructions for use of the 
medication according to the summary of product 
characteristics and patient information leaflet.
● Possibility to return the completed patient card.
Patients were not eligible if at least one of the following 
exclusion criteria were met:
● Known allergic reactions to MP-AzeFlu nasal spray 
or any of its ingredients.
● Pregnancy (or planned pregnancy during the study) 
or breastfeeding.
● Inability to provide informed consent.
● Missing consent for the collection, archiving, or 
transfer of personal data in the context of this study 
and in accordance with the observational plan.
Study Treatments
All patients received MP-AzeFlu (Dymista®; Meda 
Pharmaceuticals, Inc., a Mylan Company). MP-AzeFlu 
was dosed as outlined in the country-specific summary of 
product characteristics: 1 spray in each nostril twice daily. 
Each 0.137-mL spray delivers 137 µg of azelastine hydro-
chloride and 50 µg of fluticasone propionate.17 Physicians 
ensured the patient properly understood the instructions 
for use, as specified in the summary of product character-
istics and patient information leaflet.
Assessments of Effectiveness
On days 0, 1, 3, 7, and ~14, each patient recorded AR 
symptoms on the printed VAS form provided in a patient 
card, marking with a pencil the appropriate value on 
a printed, single-line VAS (0–100 mm), ranging from 
“not at all bothersome” (0 mm) to “extremely bothersome” 
(100 mm).
On days 0, 7, and ~14 after the start of treatment, each 
patient assessed sleep and troublesomeness in daily activ-
ities for the previous 7 days on the VAS for the following 
domains: impairment of sleep quality, impairment of daily 
school or work activity, impairment of social activity, and 
impairment of outdoor activity. VAS scores were printed 
on a patient card and included a range from “not at all 
troubled” (0 mm) to “extremely troubled” (100 mm).
Sleep quality and daily activities were assessed for the 
entire study population, as well as for four different phe-
notype subgroups (derived from the novel classification of 
immunoglobulin [Ig]E-mediated diseases provided by the 
MeDALL paper) to determine potential differences among 
heterogenous allergic phenotypes,23 including:
● Monoclonal IgE response (IgE response restricted to 
one environmental allergen without family history).
● Polyclonal IgE response (polyclonal IgE response to 
>5 environmental allergens with family history).
● Nonallergic IgE response (patients with IgE test but 
no increased total IgE value without family history).
● Intermediate phenotype (polyclonal IgE response to 
>5 environmental allergens without family history, or 
IgE response restricted to 2–5 allergens).
Statistical Methods
Statistical analyses were performed using the statistical 
software package SAS® (SAS Institute Inc.; Cary, NC, 
USA) version 9.4 or higher. Continuous variables were 
summarized by number (N), mean, and standard error. 
Categorical variables were presented in frequency distri-
bution tables with N and percentage. Percentages are rela-
tive to the total number of patients, if not stated otherwise. 
For the subgroup analyses, the percentages are relative to 
the total number of patients in the respective subgroup. 
Data analyses were explorative. Analysis of covariance for 
repeated measurements was used to assess post-baseline 
changes of VAS regarding overall symptoms of AR and 
activity impairments. The primary endpoint was displayed 
using the 95% Wilson confidence interval (CI). 
P-values<0.05 were considered statistically significant.
Results
Patients
Overall, 1,154 patients were enrolled; 51 were excluded 
because complete data were not submitted by the investi-
gator. A total of 1,103 patients were included in the ana-
lysis (male, n=474; female, n=624 [56.6%]; Table 1). Of 
these, 82 were aged from 12–17 years, 937 were aged 
from 18–65 years, and 84 were older than 65 years. The 
mean age was 40.0 years (range=12–84 years).
A total of 96.7% of patients had moderate-to-severe 
AR (3.3% had mild AR) according to ARIA classification. 
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The majority of patients (83%) had used at least one 
treatment for symptomatic AR in the past year, and 62% 
used two or more allergy medications in the past year. 
A total of 115 patients were included in subpopulation 1, 
89 made up subpopulation 2, 53 made up subpopulation 3, 
and 667 patients were included in subpopulation 4.
Patient cards were evaluable for 1,098 patients at Day 
0, 1,012 patients on the last day (~Day 14) when assessing 
sleep quality, and 1,013 patients on the last day (~Day 14) 
when assessing other domains.
Effectiveness of MP-AzeFlu
The mean VAS scores of overall AR symptoms were 73.2 mm 
at Day 0, 57.2 mm at Day 1, 46.3 mm at Day 3, 36.1 mm at Day 
7, and 27.2 mm on the last day (Figure 1). Patients reported 
severe disease at baseline (>70 mm), which improved to mild 
disease (<40 mm) following treatment with MP-AzeFlu.24 The 
responder rate, defined as a documented AR-VAS score of 
<50 mm at least once through the end of the study, was 
86.6% (95% CI=84.5–88.5; 944 patients). These patients 
were regarded as responders with controlled symptoms.
Table 1 Demographic and Baseline Characteristics
Category Patients, 
n (%)
Gender Male 474 (43.0)
Female 624 (56.6)
NR 5 (0.5)
Age, years 12–17 82 (7.4)
18–65 937 (85.0)
>65 84 (7.6)
Country Germany 450 (40.8)





Impairments Daily activities/leisure/sport 832 (75.4)
Sleep disturbance 696 (63.1)




Nasal congestion 535 (48.5)
Runny nose 359 (32.5)
Sneezing 91 (8.3)
Nasal itching 69 (6.3)
Ocular symptoms 39 (3.5)
NR 10 (0.9)
Type of AR PAR only 120 (10.9)
SAR and PAR 444 (40.3)
SAR only 435 (39.4)
NR 104 (9.4)
Types of allergen Summer pollen 656 (59.5)
Spring pollen 650 (58.9)
Dust mites 446 (40.4)
Autumn pollen 278 (25.2)




Allergic comorbidities Asthma 267 (24.2)
Atopic dermatitis/eczema 127 (11.5)
Food allergy 109 (9.9)
Severe allergic reactions 30 (2.7)
None 593 (53.8)
NR 89 (8.1)
Other comorbidities Chronic rhinosinusitis without 
nasal polyps
190 (17.2)
Chronic rhinosinusitis with nasal 
polyps
59 (5.3)










Oral nonsedating H1- 
antihistamine
506 (45.9)
Intranasal corticosteroid 471 (42.7)
Intranasal decongestant 191 (17.3)
Intranasal H1-antihistamine 177 (16.0)
Oral first-generation H1- 
antihistamine
162 (14.7)
Ocular H1-antihistamine 133 (12.1)
Oral or nebulized corticosteroid 99 (9.0)
Intranasal mast cell stabilizer 62 (5.6)
Any other 54 (4.9)
Oral leukotriene antagonist 50 (4.5)
Ocular mast cell stabilizer 42 (3.8)
Oral decongestant 26 (2.4)
Unknown 24 (2.2)
NR 164 (14.9)
Subpopulation 1 (monoclonal IgE response; no 
family history)
115 (10.4)
2 (polyclonal IgE response; with 
family history)
89 (8.1)
3 (nonallergic polyclonal IgE 
response; no family history)
53 (4.8)
4 (intermediate phenotypes) 667 (60.5)
Abbreviations: AR, allergic rhinitis; Ig, immunoglobulin; NR, not reported; PAR, 
perennial AR; SAR, seasonal AR.
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The mean patient-reported baseline VAS scores were 
55.2 mm for impairment of sleep quality, 57.6 mm for 
impairment of daily work/school activity, 55.1 mm for 
impairment of social activity, and 64.4 mm for impairment 
of outdoor activity. Day 7 and Day 14 patient cards revealed 
substantial improvements in all QoL metrics. The mean 
impairment of sleep quality (mean VAS change) decreased 
from 55.2 mm to 29.8 mm (Day 7) to 22.1 mm at 14 days. 
Significant changes were found from baseline for Day 7 and 
the last day (P<0.0001; Figure 2A). Similar results were 
seen for all subpopulations (P<0.0001; Figure 2B).
The mean impairment of daily work or school activity 
decreased from 57.6 mm to 30.4 mm (Day 7) to 23.0 mm at 
14 days. Significant changes were found from baseline for 
Day 7 and the last day (P<0.0001; Figure 3A). Similar results 
were seen among all subpopulations (P<0.0001; Figure 3B).
The mean impairment of social activity decreased from 
55.1 mm to 29.0 mm (Day 7) to 22.4 mm at 14 days. 
Significant changes were found from baseline for Day 7 
and the last day (P<0.0001; Figure 4A). Similar results 
were seen among all subpopulations (P<0.0001; Figure 4B).
The mean impairment of outdoor activity decreased 
from 64.4 mm to 32.6 mm (Day 7) to 25.0 mm at 14 
days. Significant changes were found from baseline for 
Day 7 and the last day (P<0.0001; Figure 5A). Similar 
results were seen among all subpopulations (P<0.0001; 
Figure 5B).
Moderate correlations were found between the change in 
general AR symptoms from baseline and sleep quality, activ-
ities at work or school, social activities, and outdoor activities 
(Pearson correlation coefficient=0.59–0.65; all P<0.0001).
Safety
Overall, 20 adverse drug reactions were reported in 14 
patients (1.3%) throughout the study, including epistaxis 
(n=4; 0.4%), impairment of sense of smell and taste (eg, 
dysgeusia; n=3; 0.3%), headache (n=2; 0.2%), and dys-
pnea (n=2; 0.2%). Other events were reported in one 
patient each. The duration of adverse events ranged from 
2–14 days, which resulted in recovery/resolution. All 
events were labeled as possibly related to treatment. For 
15 events, there was no impact on the administration of 
MP-AzeFlu, whereas, for the other five, it was unknown.
Discussion
In this study of 1,103 patients with AR, 86.6% responded to 
treatment with MP-AzeFlu nasal spray, which was defined as 
a VAS score <50 mm at least once during the study period. 
The severity of AR symptoms significantly decreased from 
the start of treatment (severe) through the last day of the 
Figure 1 Treatment with MP-AzeFlu decreases mean VAS scores of overall AR symptoms. 
Notes: *P<0.0001 vs baseline. The time course of mean VAS (0–100 mm) of overall AR symptoms from Day 0 to the last day (~Day 14) in the overall population. 
Abbreviations: AR, allergic rhinitis; SEM, standard error of the mean; VAS, visual analog scale.
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study period (mild). VAS scores related to QoL, including 
sleep quality, daily activities at work/school, daily social 
activities, and daily outdoor activities, also significantly 
improved from baseline. Of importance, these benefits were 
also seen in all subpopulations based on phenotypes of IgE- 
mediated disease. These results are consistent with rando-
mized controlled studies of MP-AzeFlu in which patients 
treated with MP-AzeFlu experienced a statistically signifi-
cant overall reduction on the RQLQ, as well as on each 
individual domain.25,26
Figure 2 Treatment with MP-AzeFlu decreases mean VAS scores for impairment of sleep quality in the overall population (A) and among subpopulations (B). *P<0.0001 vs 
baseline. (B) *P<0.0001 vs baseline, all subpopulations. The time course of mean VAS (mm) of impairment of sleep quality from Day 0 to the last day (~Day 14) in the overall 
population (A) and for subpopulations 1–4 (B). 
Notes: (A) Data are presented as mean (±SEM). Number of patients with available VAS data is displayed by study day. Subpopulation 1 – IgE response restricted to 1 
environmental allergen without family history; Subpopulation 2 – Polyclonal IgE response to >5 environmental allergens with family history; Subpopulation 3 – Nonallergic 
polyclonal IgE (patients with IgE test but no increased total IgE value) without family history; Subpopulation 4 – Intermediate phenotypes (polyclonal IgE response [>5 
allergens, without family history or IgE response 2–5 allergens]). 
Abbreviations: IgE, immunoglobulin E; SEM, standard error of the mean; VAS, visual analog scale.
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In the current study, patients with AR reported sig-
nificantly decreased severity of AR symptoms by an 
average of 46.2 mm from baseline through the last day 
of the study period. A VAS score improvement of 
10.0 mm was reported following 1 day of treatment in 
half of the patients, which has been defined as a clinically 
relevant improvement in symptoms and QoL by 
Bousquet et al.27 By Day 3, approximately 50% of 
patients reported an improvement of 23.0 mm or greater, 
which has been defined as a clinically relevant change in 
Figure 3 Treatment with MP-AzeFlu decreases mean VAS scores for assessment of impairment of daily activities at work or school in the overall population (A) and among 
subpopulations (B). (A) *P<0.0001 vs baseline. (B) *P<0.0001 vs baseline, all subpopulations. The time course of mean VAS (mm) of impairment of daily activities at work or 
school from Day 0 to the last day (Day ~14) in the overall population (A) and for subpopulations 1 through 4 (B). 
Notes: Data are presented as mean (±SEM). Number of patients with available VAS data is displayed by study day. Subpopulation 1 – IgE response restricted to 1 
environmental allergen without family history; Subpopulation 2 – Polyclonal IgE response to >5 environmental allergens with family history; Subpopulation 3 – Nonallergic 
polyclonal IgE (patients with IgE test but no increased total IgE value) without family history; Subpopulation 4 – Intermediate phenotypes (polyclonal IgE response [>5 
allergens, without family history or IgE response 2–5 allergens]). 
Abbreviations: IgE, immunoglobulin E; SEM, standard error of the mean; VAS, visual analog scale.
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QoL independent of initial AR severity by Demoly et al.28 
On the last day, over 75% of patients exhibited 
a clinically relevant improvement in VAS scores from 
baseline of greater than 23.0 mm, with a median change 
of 30.0 mm.
Baseline VAS scores indicated that participating 
patients with moderate-to-severe AR suffered from rela-
tively poor QoL despite previous AR treatment, including 
co-medication. With MP-AzeFlu, patients reported substan-
tial improvements in all QoL metrics assessed. MP-AzeFlu 
Figure 4 Treatment with MP-AzeFlu decreases mean VAS scores for assessment of impairment of social activity in the overall population (A) and among subpopulations (B). 
*P<0.0001 vs baseline. (B) *P<0.0001 vs baseline, all subpopulations. The time course of mean VAS (mm) of daily social activities from Day 0 to the last day (~Day 14) in the 
overall population (A) and for subpopulations 1–4 (B). 
Notes: (A) Data are presented as mean (±SEM). Number of patients with available VAS data is displayed by study day. Subpopulation 1 – IgE response restricted to 1 
environmental allergen without family history; Subpopulation 2 – Polyclonal IgE response to >5 environmental allergens with family history; Subpopulation 3 – Non-allergic 
polyclonal IgE (patients with IgE test but no increased total IgE value) without family history; Subpopulation 4 – Intermediate phenotypes (polyclonal IgE response [>5 
allergens, without family history or IgE response 2–5 allergens]). 
Abbreviations: IgE, immunoglobulin E; SEM, standard error of the mean; VAS, visual analog scale.
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not only relieves AR symptoms but also improves patient 
QoL, as indicated by better sleep quality and less impair-
ment of work, school, social, and outdoor activities after 7 
and 14 days of treatment. The results suggest that patient 
QoL improvements were the result of fewer AR symptoms, 
which is supported by significant correlations between the 
reported change in general AR symptoms from baseline and 
QoL metrics. The benefits of MP-AzeFlu on QoL were 
consistent, regardless of the phenotype of IgE-mediated 
disease, suggesting that MP-AzeFlu is effective at 
Figure 5 Treatment with MP-AzeFlu decreases mean VAS scores for assessment of impairment in outdoor activity in the overall population (A) and among subpopulations 
(B). (A) *P<0.0001 vs baseline. (B) *P<0.0001 vs baseline, all subpopulations. The time course of mean VAS (mm) of impairment in daily outdoor activities from Day 0 to the 
last day (~Day 14) in the overall population (A) and for subpopulations 1–4 (B). 
Notes: Data are presented as mean (±SEM). Number of patients with available VAS data is displayed by study day. Subpopulation 1 – IgE response restricted to 1 
environmental allergen without family history; Subpopulation 2 – Polyclonal IgE response to >5 environmental allergens with family history; Subpopulation 3 – Non-allergic 
polyclonal IgE (patients with IgE test but no increased total IgE value) without family history; Subpopulation 4 – Intermediate phenotypes (polyclonal IgE response [>5 
allergens, without family history or IgE response 2–5 allergens]). 
Abbreviations: IgE, immunoglobulin E; SEM, standard error of the mean; VAS, visual analog scale.
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improving QoL across IgE subgroups. These findings pro-
vide support to previous studies demonstrating improved 
olfaction and sleep quality following MP-AzeFlu treatment 
in patients with AR.18,29
Current ARIA recommendations are to use either an 
intranasal corticosteroid (INCS), intranasal H1-antihistamine 
(INAH), or the combination of INCS and azelastine in 
patients with seasonal or perennial AR.1,30 These data provide 
an important new addition to the evidence base supporting 
improved QoL with MP-AzeFlu in patients with moderate-to- 
severe AR taking MP-AzeFlu as a first-line therapy as recom-
mended by ARIA or later in the continuum of care.
Based on real-world evidence, the combination of oral 
H1-antihistamines plus INCS is not more effective than 
INCS treatment alone.27 Furthermore, the combination of 
INCS and INAH has been shown to be more effective 
than INCS treatment alone. Medications containing H1- 
antihistamines, such as MP-AzeFlu, have been shown to 
be effective within minutes. When considering the level 
of control and co-medication, MP-AzeFlu has been 
shown to be more effective than INCS treatment.
Limitations to an observational study in a real-life 
setting are inherent, including the lack of randomization 
and the potential presence of confounding bias; however, 
the effect of MP-AzeFlu on QoL was consistent with 
randomized controlled trials. Pollen counts were not 
assessed during the study period; however, no relevant 
changes in exposure are expected during the 2-week treat-
ment duration. In addition, there was no use of a control or 
placebo. However, the results of this study are not 
intended to be comparative with other treatments, and the 
current results demonstrate QoL improvements for patients 
taking MP-AzeFlu. Advantages of this study include the 
ability to gather large amounts of data quickly and to 
explore current clinical practice patterns.
Conclusion
The use of MP-AzeFlu improved severity of AR symptoms 
and patient QoL by improving the impact on sleep and daily 
activities. The first-line use of MP-AzeFlu as recommended 
by ARIA results in clinically significant improvements for 
patients with AR, regardless of phenotype.
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